Bipiperidinyl carboxylic acid amides as potent, selective, and functionally active CCR4 antagonists

Chemical Biology and Drug Design

Volumn 70, Issue 3, 2007, Pages 268-272

  Kuhn, Cyrille F ^a   Bazin, Marc ^a   Philippe, Laurence ^a   Zhang, Jiansu ^a   Tylaska, Laurie ^a   Miret, Juan ^a   Bauer, Paul H ^a  

^a PFIZER INC   (United States)

Author keywords

Bipiperidinyl carboxylic acid amide; CCR4; Chemokine; Chemotaxis; Parallel synthesis

Indexed keywords

BIPIPERIDINYL CARBOXYLIC ACID AMIDE DERIVATIVE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CHEMOTAXIS; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; IC 50; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

AMIDES; BIPERIDEN; CARBOXYLIC ACIDS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; RECEPTORS, CHEMOKINE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548155743     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00551.x     Document Type: Article

References (14)

1. Onuffer J.J., Horuk R. (2002) Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharm Sci 10 : 459 467.
2. Carter P.H. (2002) Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr Opin Chem Biol 6 : 510 525.
3. Kim S.H., Cleary M.M., Fox H.S., Chantry D., Sarvetnick N.J. (2002) CCR4-bearing T cells participate in autoimmune diabetes. Clin Invest 110 : 1675 1686.
4. Ishida T., Iida S., Akatsuka Y., Ishii T., Miyazaki M., Komatsu H., Inagaki H., Okada N., Fujita T., Shitara K., Akinaga S., Takahashi T., Utsunomiya A., Ueda R. (2004) The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia/lymphoma. Clin Cancer Res 10 : 7529 7539.
5. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 : 942 949.
6. 2+ flux assays for high-throughput screening. J Biomol Screen 10 : 780 787.
7. Purandare A.V., Sommerville J.E. (2006) Antagonists of CCR4 as immunomodulatory agents. Curr Top Med Chem 6 : 1335 1344.
8. Wang X., Xu F., Xu Q., Mahmud H., Houze J., Zhu L., Akerman M., Tonn G., Dairaghi D.J., Collins T.L., Medina J.C. (2005) Discovery and Optimization Of 2-Aminothiazole Derivatives as CCR4 Antagonists. Abstract MEDI-058, 230th National Meeting of the American Chemical Society, Washington, DC.
9. Purandare A.V., Wan H., Gao A., Sommerville J.E., Burke C., Vaccaro W., Yang X., McIntyre K.W., Poss M.A. (2007) Core exploration in optimization of chemokine receptor CCR4 antagonists. Bioorg Med Chem Lett 17 : 679 682.
10. Allen S., Newhouse B., Anderson A.S., Fauber B., Allen A., Chantry D., Eberhardt C., Odingo J., Burgess L.E. (2004) Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists. Bioorg Med Chem Lett 14 : 1619 1624.
11. Hansen J.D., Newhouse B.J., Allen S., Anderson A., Eary T., Shiro J., Gaudino J., Laird E., Allen A.C., Chantry D., Eberhardt C., Burgess L.E. (2006) Synthesis of spirolactams and spiropiperidines as CCR4 receptor antagonists. Tetrahedron Lett 47 : 69 72.
12. Burdi D.F., Chi S., Mattia K., Harrington C., Shi Z., Chen S., Jacutin-Porte S. et al. (2007) Small molecule antagonists of the CC chemokine receptor 4 (CCR4). Bioorg Med Chem Lett 17 : 3141 3145.
13. ® OJ-H HPLC column with novel polar cosolvent eluent systems. Chirality 18 : 437 445.
14. Gladue R.P., Cole S.H., Roach M.L., Tylaska L.A., Nelson R.T., Shepard R.M., McNeish J.D., Ogborne K.T., Neote K.S. (2006) The human specific CCR1 antagonist CP-481,715 inhibits cell infiltration and inflammatory responses in human CCR1 transgenic mice. J Immunol 176 : 3141 3148.